BIT Capital GmbH Has $811,000 Stake in Leap Therapeutics, Inc. (NASDAQ:LPTX)

BIT Capital GmbH grew its stake in shares of Leap Therapeutics, Inc. (NASDAQ:LPTX) by 248.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 282,008 shares of the company’s stock after acquiring an additional 201,008 shares during the quarter. BIT Capital GmbH owned about 0.74% of Leap Therapeutics worth $811,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the company. Geode Capital Management LLC boosted its holdings in shares of Leap Therapeutics by 18.0% in the 3rd quarter. Geode Capital Management LLC now owns 329,291 shares of the company’s stock valued at $847,000 after purchasing an additional 50,194 shares in the last quarter. HighTower Advisors LLC bought a new stake in shares of Leap Therapeutics in the third quarter worth $65,000. HB Wealth Management LLC increased its stake in shares of Leap Therapeutics by 103.2% in the fourth quarter. HB Wealth Management LLC now owns 51,500 shares of the company’s stock valued at $150,000 after buying an additional 26,150 shares during the period. Monaco Asset Management SAM acquired a new stake in Leap Therapeutics during the 4th quarter valued at approximately $592,000. Finally, Key Client Fiduciary Advisors LLC raised its stake in Leap Therapeutics by 12.2% during the fourth quarter. Key Client Fiduciary Advisors LLC now owns 361,253 shares of the company’s stock worth $1,039,000 after buying an additional 39,330 shares during the last quarter. 30.46% of the stock is currently owned by institutional investors and hedge funds.

Leap Therapeutics Stock Performance

Shares of LPTX stock opened at $0.45 on Thursday. Leap Therapeutics, Inc. has a 52 week low of $0.39 and a 52 week high of $4.79. The firm’s 50-day simple moving average is $0.83 and its two-hundred day simple moving average is $2.21. The firm has a market cap of $17.38 million, a price-to-earnings ratio of -0.23 and a beta of 0.35.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Baird R W downgraded Leap Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, January 29th. HC Wainwright lowered shares of Leap Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, January 29th. Finally, Robert W. Baird cut Leap Therapeutics from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $9.00 to $1.25 in a research note on Wednesday, January 29th.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.